Innovative Medicines Initiative (IMI): pubblicato ufficialmente il nuovo bando

Di seguito i 15 topics inclusti nella call:

• Topic 1: Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
• Topic 2: Genome-Environment Interactions in Inflammatory Skin Disease
• Topic 3: The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
• Topic 4: Mitochondrial Dysfunction in Neurodegeneration
• Topic 5: Support and coordination action for the projects in the neurodegeneration area of the Innovative Medicines Initiative
• Topic 6: A sustainable European induced pluripotent stem cell platform
• Topic 7: Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice
• Topic 8: Human tumour microenvironment immunoprofiling
• Topic 9: ConcePTION – Continuum of Evidence from Pregnancy Exposures, Reproductive Toxicology and Breastfeeding to Improve Outcomes Now
• Topic 10: Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
• Topic 11: Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
• Topic 12: Pilot programme on a Clinical Compound Bank for Repurposing: Cardiovascular diseases and diabetes
• Topic 13: Pilot programme on a Clinical Compound Bank for Repurposing: Respiratory diseases
• Topic 14: Pilot programme on a Clinical Compound Bank for Repurposing: Neurodegenerative diseases
• Topic 15: Pilot programme on a Clinical Compound Bank for Repurposing: Rare/orphan diseases

Il bando adotta una valutazione a due step, con la scadenza per la Fase 1 fissata per tutti i topic al 28 febbraio 2018.

Maggiori informazioni sulla relativa pagina del sito web ufficiale IMI. Per gli interessati, dal 27 novembre al 15 dicembre sono programmati una serie di webinars dedicati a vari aspetti della futura call.